Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
Benign lymphoid hyperplasia is a disorder characterized by polyclonal lymphocytic infiltration of orbital tissues, predominantly with B-cells. Rituximab is a monoclonal antibody directed against CD20, a B-cell marker. Two patients with recurrent orbital masses involving the lacrimal glands were treated with rituximab. The diagnosis of benign lymphoid hyperplasia with predominance of CD20 cells was confirmed in both cases based on a surgical biopsy. Both patients had been previously treated with standard therapies, including high-dose steroids, and one patient had failed external-beam radiation therapy. They both responded well to treatment with intravenous rituximab. Neither patient experienced any side effects associated with rituximab.
Ho
Hao H
HH
Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA.
Savar
Aaron
A
Samaniego
Felipe
F
Manning
John
J
Kasyan
Armen
A
Pro
Barbara
B
Esmaeli
Bita
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008279:Magnetic Resonance Imaging; D009916:Orbital Diseases / Q000188:drug therapy*; D019310:Pseudolymphoma / Q000188:drug therapy*; D000069283:Rituximab; D055815:Young Adult
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab